Differentiation between cholangiocarcinoma and hepatocellular carcinoma with target sign on diffusion-weighted imaging and hepatobiliary phase gadoxetic acid-enhanced MR imaging: Classification tree analysis applying capsule and septum. Issue 92 (July 2017)

• Record Type: Journal Article
• Authors: Min, Ji Hye; Kim, Young Kon; Choi, Seo-Youn; Jeong, Woo Kyoung; Lee, Won Jae; Ha, Sang Yun; Ahn, Soohyun; Ahn, Hyeon Seon
• Is Part Of: European journal of radiology. Issue 92(2017)
• Page Start: 1
• Page End: 10
• Publication Date: 2017-07
• Subjects: CTA classification tree analysis -- HCC hepatocellular carcinoma -- HBP hepatobiliary phase -- DWI diffusion-weighted imaging -- ICC intrahepatic cholangiocarcinoma -- EASL European Association for the Study of the Liver -- AASLD American Association for the Study of Liver Diseases -- LI-RAD Liver Imaging Reporting and Data System -- ADC apparent diffusion coefficient; Gadoxetic acid -- Cholangiocarcinoma -- Hepatocellular carcinoma -- Target sign -- Hepatobiliary phase -- Diffusion-weighted image; Medical radiology -- Periodicals; Radiology -- Periodicals; Radiologie médicale -- Périodiques; Medical radiology; Periodicals; 616.075705
• DOI: 10.1016/j.ejrad.2017.04.008
• Languages: English
• ISSNs: 0720-048X

Abstract

Highlights: Target sign on HBP or DWI was a newly introduced imaging feature suggestive of ICC. Some HCCs such as scirrhous HCC might also show a target sign on HBP or DWI. Capsule and septum on MR imaging helps discriminating between ICCs and HCCs. CTA applying the capsule and septum may be useful for guiding correct diagnosis. CTA achieved acceptable sensitivity and specificity for discrimination of tumors. Abstract: Objectives: To assess the usefulness of classification tree analysis (CTA) for discrimination of hepatocellular carcinoma (HCC) with target sign on hepatobiliary phase (HBP) and/or diffusion-weighted image (DWI) from intrahepatic cholangiocarcinoma (ICC). Methods: This retrospective study was approved by the institutional review board. From among the 811 patients with histopathologically proven 79 ICCs and 732 HCCs, 69 patients with 69 (87.3%) ICCs and 115 patients with 115 HCCs (15.7%) including 25 scirrhous HCCs and 10 HCCs with central scar that showed the target sign either on HBP or on DWI were included. Two radiologists evaluated the presence of capsule, septum, and arterial enhancement pattern on MR imaging. Capsule, septum, arterial enhancement pattern, and target sign on HBP or DWI were used to classify the tumors using CTA. Results: On CTA, capsule was the initial predictor for assessing the probability of tumors being HCC. The CTA model demonstrated a sensitivity of 86.1%, specificity of 76.8%, and accuracy of 82.6% for discriminating between ICCs and HCCs. In 115 HCCs, only 16 (13.9%) tumors were misclassified as high probability of ICC, and 64.0% (16/25) scirrhous HCCs and 90.0% (9/10) HCCs with central scar were correctly classified as high probability of HCC. Conclusions: Target sign either on HBP or on DWI was shown in 87.3% (69/79) of ICCs and 15.7% (115/732) of HCCs. The CTA applying capsule and septum may be useful for guiding correct diagnosis of atypical HCCs with the target sign from ICCs.